CLINICAL AND EXPERIMENTAL MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2025-03-02 ms6000000487015005 来自山东省

审稿速度:2.0 | 投稿命中率:95.0
经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受

10 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-06-07 ms2000001773096306 来自江苏省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况

58 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2024-08-26 ms9000001272921253 来自福建省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：细胞治疗;肿瘤免疫
经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof.

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2024-04-13 国统乃我辈之愿来自海南省

去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗

100 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-12-24 ms2000001657204792 来自上海

一个月了，还在邀请审稿人，要是还邀请不到真开始慌了

129 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2024-04-05 罗磊来自湖北省

审稿速度:1.0
经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收

132 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-12-21 39314679eccv 来自湖北省

这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？

110 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-11-07 1226054bm42暂无昵称来自广东省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;Meta分析
经验分享：投稿的一篇Meta分析
6月1号投稿
6月3号送审
10月30号返修
11月1号修回
11月7号接收
外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错

100 0

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-10-16 仅叹来自重庆

投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。
——————No.1——————
2022.9.30 submission received
2022.9.30 reviewers invited (21)
2022.12.28 reviewers invited (22)
2023.1.10 无审稿人接受审稿邀请→rejected
——————No.2——————
2023.5.17 submission received
2023.5.18 reviewers invited (27)
2023.5.25 one reviewer accepted to review
2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿

122 0

[GetPortalCommentsPageByObjectIdResponse(id=2254173, encodeId=0b6222541e34e, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：我一月份投的搞，1.31回审稿意见，2.1修回，2.28接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6809488632, createdName=ms6000000487015005, createdTime=Sun Mar 02 06:17:15 CST 2025, time=2025-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2141318, encodeId=d23b214131831, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2.18投稿 4.15给返修意见 4.25第一次翻修提交至今一点消息都没有说还在找编辑和评审人无语啊什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bb8249992, createdName=ms2000001773096306, createdTime=Wed Jun 07 21:17:25 CST 2023, time=2023-06-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省)]

2023-07-04 国统乃我辈之愿来自海南省

偏重的研究方向：临床实验研究
经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！

138 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务